All News

Accelerated review of "me-too" products would increase market competition entailing a drug price competition, said experts at a panel discussion during a recent biotechnology meeting.

More than half of physicians in a nationwide survey are willing to see their patients over video, claiming the work-life balance to be the most common reason for the potential change in health system referrals.

The Core Quality Measures Collaborative Workgroup, initiated by AHIP and payer organizations, seeks to reduce, refine, and relate the healthcare delivery process.

The Supreme Court may have kept subsidies available to all Americans regardless of whether their state has set up its own exchange, but some people still refuse to purchase coverage, and they're perfectly happy remaining uninsured.

Researchers at the MD Anderson Cancer Center have developed a blood test that can detect very early stages of pancreatic cancer before disease progression.

In a triumphant win for President Obama's Affordable Care Act and millions of Americans, the Supreme Court of the United States ruled against the plaintiffs in the case King v. Burwell and upheld the availability of subsidies for individuals on the federally facilitated marketplace.

The JAMA authors recommend that HHS and the US Department of Agriculture pay attention to DGAC's recommendations on fat intake, which do not include an upper limit on total fat consumption.

NICE has updated and redesigned its guideline to support primary care physicians to recognize the signs and symptoms of 37 different cancers and refer people for the right tests faster.

A new study summarizing network size by physician, not just hospital participation, determined that 41% of networks on the marketplaces can be considered small or x-small and contain just 25% or less of office-based physicians in the area.

Researchers of The Commonwealth Fund discovered that 95% of individuals with Medicaid coverage over the past year had a regular doctor and 55% of this population reported receiving excellent or very good care.

A clinical trial at the University of Alabama will be enrolling patients in the first-ever study of an open-label placebo in cancer.

Current adherence measures rely on lots of human interaction-something that is not scalable given the need. Avatars will become the norm in the near future.

A more selective use of biomarker testing for patients with breast cancer could save millions of dollars without compromising the care they receive, according to the results of a study published in The American Journal of Surgical Pathology.

Among the 20 chronic conditions with the highest impact on the Medicare population, some have no quality measure, which limits Medicare's ability to pay for value.

There have been numerous attempts to repeal part or all of the Affordable Care Act since it became law, and the Congressional Budget Office admits its estimates on the effect of repealing the law are all subject to "substantial uncertainty."

When evaluating the cost-effectiveness of 4 different interventions to prevent or reduce childhood obesity, researchers found that the benefit of these interventions surpassed the current clinical interventions to treat obesity.

Concern from Congress about the potential cost of widespread use has kept telehealth from expanding in traditional Medicare. But things are starting to change as ACOs gain the ability to use telehealth, and rule changes allow its use for mental health and other services.

A researcher from the University of Missouri and her team, studied the impact of closure of a large, safety-net agency on it's clients and on smaller agencies to which the clients were referred.

As electronic health records increasingly grow more important in the healthcare environment, so too does cybersecurity.

A framework that primarily considers clinical benefit, toxicity, and cost of new treatments was released today by ASCO. A presscast complementing the release described the framework as a tool for providers to discuss value of new treatments with patients, compared with the standard of care.

During the first year of health coverage expansion under the Affordable Care Act, many primary care providers said the number of patients they saw increased, but reported no compromise in quality of care provided, according to a study from the Kaiser Family Foundation and The Commonwealth Fund.

Although drug development is expensive, the high prices being charged for some specialty drugs, like Sovaldi, are not required to induce innovation, Len M. Nichols, PhD, wrote Monday for Morning Consult.

The authors analyzed data from 2007 to 2012 to report their findings. They say that population health efforts must go beyond screenings for chronic conditions associated with overweight and obesity and identify those at normal weight in danger of weight gain.

A study published in the New England Journal of Medicine says a CT scan following a first venous thromboebolism event may not benefit in detecting cancer.

Using mass-spectrometry—based phosphoproteomics, researchers at the Moffit Cancer Center have identified a mechanism by which BRAF/PTEN-null melanoma cells develop resistance to BRAF inhibitors.

A new report from the Kaiser Family Foundation analyzed the impact of gaining health insurance through the Affordable Care Act for low-income families.

This week 3 states received approval to set up their own state exchanges in the even the Supreme Court removes subsidies in the federally facilitated marketplace, and the deadline passed for stakeholders to respond to CMS' proposed rules for mental health parity in Medicaid managed care.

One of the most vocal physicians about the high prices of cancer drugs, Peter Bach, MD, MAPP, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, recently led the effort to create a value-based calculator to determine the true worth of cancer drugs.

In a national study that included 9 million Americans, researchers found that the hospital a patient experiencing post-surgical complications returns to for readmission has an impact on the quality of care the patient receives.

Earlier this week, the FDA heard from various stakeholders and experts from the healthcare industry on how delays in the generic approval process impact healthcare costs.